This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3M Launches 3M M*Modal CDI Engage One for Healthcare Market
by Zacks Equity Research
3M's (MMM) 3M M*Modal CDI Engage One offers real-time clinical insight to clinical documentation improvement specialists, clinicians and coding teams.
Honeywell (HON) Commissions Technology for Zhejiang Satellite
by Zacks Equity Research
Zhejiang Satellite uses Honeywell's (HON) C3 Oleflex technology for the production of polymer-grade propylene at its facility in China.
General Electric to Get Roughly $3B From Stake Sale in BHGE
by Zacks Equity Research
General Electric's (GE) offering of Baker Hughes' shares to the public and Baker Hughes' decision to buy back own shares will likely raise roughly $3 billion. Funds will help in reducing debts.
Diversified Operations Industry Near-Term Prospects Bright
by Payal Jalan
Technological advancements, favorable conditions in end markets like aerospace and defense, restructuring efforts and pro-growth policies of the government are making conglomerates a favorable investment destination.
UTX or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
General Electric to Lose Controlling Stake in Baker Hughes
by Zacks Equity Research
General Electric's (GE) offering of Baker Hughes' shares to the public and Baker Hughes' decision to buy back own shares comply with the restructuring plans announced in June 2018.
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Danaher (DHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Danaher's Senior Notes Offerings to Fund BioPharma Buyout
by Zacks Equity Research
Danaher's (DHR) subsidiary prices euro 6.25 billion worth of senior notes offerings. The net proceeds will be used for paying for the pending acquisition of General Electric's BioPharma business.
Simple Market Timing Strategies That Work - September 02, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Danaher (DHR) Stock Rises 38% YTD: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR) outperforms its industry and the S&P 500 year to date on solid financial performances, buyout gains, solid product demand, shareholder-friendly policies and other factors.
General Electric's (GE) GECAS Unit to Divest PK AirFinance
by Zacks Equity Research
General Electric's (GE) financial services unit GE Capital's divestment of PK AirFinance will help it progress on its plan to divest assets worth $10 billion in 2019.
Carlisle (CSL) Rises 41% YTD: What's Driving the Stock?
by Zacks Equity Research
Carlisle (CSL) surges year to date, outperforming the industry and the S&P 500. Healthy end-market businesses, acquired assets and shareholder-friendly policies are supporting its share price rally.
UTX or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
Danaher Gains From Rising Product Demand Despite High Costs
by Zacks Equity Research
Danaher's (DHR) solid product portfolio and focus on innovation are boons. However, rise in costs and expenses as well as high debts and forex woes are concerning.
Danaher (DHR) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UTX vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTX vs. DHR: Which Stock Is the Better Value Option?
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
by Zacks Equity Research
Is (DHR) Outperforming Other Conglomerates Stocks This Year?
ITT's Q2 Earnings and Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
ITT's second-quarter earnings and revenues rise year over year on the back of solid performance across Industrial Process and Connect & Control Technologies segments.
Macquarie Infrastructure's (MIC) Q2 Earnings Decline Y/Y
by Zacks Equity Research
Macquarie Infrastructure's (MIC) second-quarter earnings decline year over year on account of higher selling, general and administrative and depreciation costs and rise in interest expenses.
General Electric (GE) Beats Q2 Earnings Estimates, Ups View
by Zacks Equity Research
General Electric's (GE) second-quarter 2019 earnings decline year over year due to weakness in sales and margins. However, earnings beat estimates by 41.7%. It raises earnings view for 2019.
3M (MMM) Q2 Earnings and Sales Beat Estimates, Down Y/Y
by Zacks Equity Research
3M's (MMM) second-quarter 2019 results suffer from forex woes, adverse impact of divestitures and weak organic sales. However, its earnings and sales surpass respective estimates.
Carlisle (CSL) Q2 Earnings & Revenues Top Estimates, Up Y/Y
by Zacks Equity Research
Carlisle's (CSL) second-quarter 2019 results benefit from growth in organic sales, acquired assets and margin improvement.
United Technologies' (UTX) Q2 Earnings and Revenues Beat
by Zacks Equity Research
United Technologies' (UTX) Q2 earnings jump year over year on the back of solid performance across most of its segments.
Crane (CR) Beats Earnings Estimates in Q2, Declares Dividend
by Zacks Equity Research
Crane's (CR) second-quarter 2019 results gain from a decline in costs and expenses, and hence, better margin profile. It declares a dividend to be paid in September.
CR vs. DHR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CR vs. DHR: Which Stock Is the Better Value Option?